Xolair (omalizumab) / Roche, Novartis - LARVOL DELTA

Moderate-to-severe chronic spontaneous urticaria is associated with increased risk of immune-mediated diseases: A population-based study. (PubMed, PLoS One) - "We propensity matched patients with ≥2 ICD-10 diagnoses of idiopathic urticaria treated with omalizumab, dupilumab, or cyclosporine (moderate-to-severe disease) to age-, sex-, race-, ethnicity-, comorbidity-, and family history-matched counterparts who were never treated with biologics or cyclosporine (mild disease). Patients with moderate-to-severe CSU had a significantly increased risk of developing rheumatoid arthritis OR=1.34 (95% CI: 1.12 to 1.60, p = 0.001) and Sjögren's syndrome OR=1.04 (1.63-2.56, p < 0.0001), after adjusting for clinical factors and multiple hypothesis testing (Bonferroni's alpha ≤0.00333). Moderate-to-severe CSU is associated with an increased risk of rheumatoid arthritis and Sjögren's syndrome compared to mild CSU."

Journal • Retrospective data • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome • Urticaria

Immunopathogenic Endotypes of Asthma: From Type 2 and Non-Type 2 Inflammation to Precision Therapeutic Strategies. (PubMed, J Asthma) - "Depending on type of inflammation, eosinophilic (anti-IL-5 (mepolizumab) and mixed inflammation (dupilumab/tezepelumab) and high IgE (omalizumab) biomarkers are pivotal in stratifying phenotypes, predicting exacerbation, and informing targeted biologics, including anti-IL-5 (mepolizumab) and dupilumab/tezepelumab, respectively. This synthesis heralds a paradigm shift of empirical symptom control to personalized interventions, reduction of exacerbations, lessening of overtreatment, and the identification of new targets in multi-omics era to overcome the unmet needs of severe, steroid-resistant asthma."

Journal • Review • Allergy • Asthma • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • IL33 • IL4 • IL5

Influence of newly initiated biologic therapy on the dose of ICS therapy - Data from the German Asthma Net. (PubMed, J Allergy Clin Immunol Pract) - "ICS reduction was associated with improved patient-reported outcomes without worsening exacerbations, lung function or FeNO."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection. (PubMed, Antibodies (Basel)) - "Between February 2024 and September 2025 the landscape changed: dupilumab (anti-IL-4Rα) and the first oral Bruton tyrosine kinase (BTK) inhibitor, remibrutinib, were approved for CSU; omalizumab biosimilars reached the market; the higher-affinity anti-IgE antibody ligelizumab was discontinued; and the investigational anti-KIT antibody barzolvolimab advanced to phase 3-creating new therapeutic opportunities for non-responders while leaving the choice among these second-line options unresolved by current guidelines. Current evidence appears to support omalizumab as first-line, with mechanism-guided second-line choices conditioned on endotype, comorbidity, prior biologic exposure and safety. The complexity of CSU and the incomplete response to currently available therapies support a patient-tailored approach to treatment selection."

Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Prescribing characteristics of asthma biologics used in an adult cystic fibrosis clinic (NACFC 2026) - "The most common initial biologic used was dupilumab with 25 patients initiated on this, with 5 started on benralizumab, 3 on omalizumab and 1 on mepolizumab. Given their favorable safety data, the potential risks of inhaled steroids in cystic fibrosis, and the high prevalence of asthma and T2 inflammation in cystic fibrosis, asthma biologics represent an attractive treatment option in cystic fibrosis. More research is needed, however, to determine their safety, efficacy and the optimal biomarkers to predict response in cystic fibrosis."

Clinical • Allergic Bronchopulmonary Aspergillosis • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Cystic Fibrosis • Eosinophilic Esophagitis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pruritus • Pulmonary Disease • Respiratory Diseases • Sinusitis

Real-world effectiveness of T2-targeted biologics in patients with chronic obstructive pulmonary disease (COPD) (ERS 2026) - " This retrospective, monocentric study at Foch Hospital included COPD patientstreated for ≥ 3 months with Th2-targeted biologics (benralizumab, dupilumab, mepolizumab,omalizumab, or tezepelumab) between 2018 and 2025. T2-targeted biologics significantly reduce exacerbation frequency and OCS usein COPD patients, regardless of an associated asthma phenotype."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases

Key guidelines in urticaria (EADV 2026) - "Treatment should aim at complete disease control and improved quality of life, following a stepwise strategy that includes second-generation H1-antihistamines, dose escalation when needed, and timely advancement to biologic (e.g., omalizumab, dupilumab) or immunomodulatory therapies in insufficiently controlled disease. - To use a treat-to-target algorithm aiming at complete disease control and improved quality of life. - To recognise recent advances in urticaria management, including biomarker-guided thinking and emerging targeted therapies, and to assess their potential impact on clinical practice."

Cardiovascular • Dermatology • Immunology • Urticaria

Biologics in children with severe asthma: a consensus statement on choosing and stopping biologics A statement from the European Respiratory Society (ERS) Clinical Research Collaboration SPACE, on behalve of the SPACE Delphi Study Group (ERS 2026) - "Statements on the preferred choice of biologics in case of asthma plus co-morbidities reached highest levels of agreement: for dupilumab 98.2% if atopic dermatitis (median 5; IQR 0), 87.5% if nasal polyps (median 4, IQR1), 91.1 % if eosinophilic esophagitis (median 5; IQR 1). For omalizumab 80.4% if urticaria (median 4; IQR 1), 85.7% if food allergy (median 4; IQR 1)...Less consensus was achieved on if and how to stop biologics. Conclusion This consensus among an expert international panel provides guidance on the choice of biologic in peadiatric severe asthma phenotypes and in the timing of cessation of treatment."

Clinical • Asthma • Atopic Dermatitis • Dermatitis • Eosinophilic Esophagitis • Food Hypersensitivity • Gastrointestinal Disorder • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Urticaria

Dual Biologic Therapy in Severe Asthma: Real-World Experience at Hospital Clínic de Barcelona (ERS 2026) - "Prior biologics included omalizumab, mepolizumab, benralizumab, reslizumab, and dupilumab...Among the 5 evaluable patients: median annualized exacerbations decreased from 3.0 to 0.5/year; median ACT improved from 18 to 21 points; mean FEV₁ increased 240 mL; 4/5 reduced/discontinued systemic corticosteroids (median 7.5 to 2.5 mg prednisone daily)... Dual therapy with mepolizumab and dupilumab or omalizumab showed clinical benefit in selected patients with severe refractory asthma, particularly those with EGPA, nasal polyposis, and atopic dermatitis. The combination was well-tolerated with improvements in asthma exacerbations, lung function, and corticosteroid-sparing."

Clinical • Real-world • Real-world evidence • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Eosinophilia • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases

Biologics in pediatric chronic rhinosinusitis with nasal polyps: A systematic review of efficacy and safety. (PubMed, Pediatr Allergy Immunol) - "Dupilumab, omalizumab, and mepolizumab showed signals of potential benefit in selected type 2 inflammatory phenotypes, but sinonasal outcomes were inconsistently reported. However, current evidence is predominantly based on case series and indirect cohorts; therefore, conclusions should be considered cautious and hypothesis-generating. Prospective pediatric studies with standardized sinonasal outcomes and longer follow-up are required."

Journal • Review • Chronic Rhinosinusitis With Nasal Polyps • Conjunctivitis • Cystic Fibrosis • Eosinophilia • Genetic Disorders • Immunology • Musculoskeletal Pain • Nasal Polyps • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Pediatrics • Pulmonary Disease • Respiratory Diseases • Sinusitis

Treatment: now and future (EADV 2026) - "In addition to omalizumab (anti-IgE antibody), dupilumab (anti-IL-4Rα antibody) and remibrutinib (Bruton's tyrosine kinase inhibitor) are now approved for the treatment of chronic spontaneous urticaria in Europe. Learning objectives: - Update of the international urticaria guideline, with focus on the currently recommended treatment algorithm. - Clinical trial data and real-world-evidence for newly approved treatments of chronic spontaneous urticaria - Overview of emerging treatments for chronic spontaneous and inducible urticaria"

Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Biologics for Children and Adolescents with Asthma: A Systematic Review and Exploratory Indirect Comparative Analysis. (PubMed, J Asthma Allergy) - "Three placebo-controlled pediatric trials evaluating omalizumab, dupilumab, and mepolizumab contributed to the primary analysis. Current adjusted indirect estimates do not establish a biologic hierarchy. Phenotype-stratified head-to-head pediatric trials remain necessary."

Journal • Review • Asthma • Immunology • Inflammation • Pediatrics • Pulmonary Disease • Respiratory Diseases

In-clinic and at-home administration of injectable biologics for severe asthma and CRSwNP places a considerable time burden on patients and HCPs: Pooled results from a time and motion study (ERS 2026) - "A time model included dosing frequency (dupilumab [Q2W], mepolizumab [Q4W], omalizumab [Q4W], tezepelumab [Q4W] and benralizumab [Q8W]). Injectable biologic administration was associated with considerable HCP and patient time, with higher dosing frequency driving greater in-clinic administration burden. Funding: GSK (214575)"

Clinical • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Respiratory Diseases

Blocking the IL4/IL-13 pathway improves airway resistance in severe asthma in real-life (ERS 2026) - " This retrospective analysis included 86 patients suffering from severe asthma initiated with different biologicals (Dupilumab (N=34), Tezepelumab (N=21), Mepolizumab (N=18), Benralizumab (N=8) and Omalizumab (N=5)) at the University of Liège, Belgium. Our study shows a significant improvement in airway resistances in both large and small airways in patients receiving Dupilumab for 6 months. The absence of impact of Dupilumab on other IOS measures and the absence of significant changes with other targeted treatments have to be confirmed in larger cohorts."

Clinical • Asthma • Immunology • Respiratory Diseases • IL13 • IL4

Risk of lymphoma in patients with asthma treated with Dupilumab compared with other biologic agents: A real-world cohort study (ERS 2026) - "In this large real-world cohort, dupilumab was not associated with increased risks of lymphoma or other malignancies compared with omalizumab, mepolizumab, or benralizumab in patients with asthma, supporting its long-term safety regarding cancer risk."

Clinical • Real-world • Real-world evidence • Asthma • Cutaneous T-cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Immunology • Lymphoma • Prostate Cancer • Respiratory Diseases • Solid Tumor • T Cell Non-Hodgkin Lymphoma • IL4R

Real-World Treatment Escalation Patterns of Biologics and Functional Endoscopic Sinus Surgery in Chronic Rhinosinusitis (CRS): A Nationwide Database Study. (PubMed, Int Forum Allergy Rhinol) - No abstract available

HEOR • Journal • Real-world evidence • Otorhinolaryngology • Respiratory Diseases • Sinusitis

BREATHE study: T2 biomarkers and treatment patterns in severe asthma patients with and without comorbid CRSwNP. (ERS 2026) - "Drug choices differed: Yes-NP used more dupilumab and mepolizumab, while No-NP used more benralizumab and omalizumab. FeNO differences were largest at -12m and diminished over time, suggesting inflammatory control after treatment optimization. CRSwNP status strongly shaped biologic choice, reinforcing its value as a precision trait for earlier targeted therapy."

Biomarker • Clinical • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilia • Immunology • Inflammation • Nasal Polyps • Respiratory Diseases

IMPROVED CLINICAL OUTCOMES WITH DUPILUMAB VS OMALIZUMAB IN PATIENTS WITH SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, COEXISTING ASTHMA, AND ANOSMIA IN EVEREST (CHEST 2026) - No abstract available

Clinical • Clinical data • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Variability of Impulse Oscillometry parameters as Predictor of Severe Asthma Remission (ERS 2026) - "This prospective study included patients receiving Benralizumab (B), Dupilumab (D), Mepolizumab (M) or Omalizumab (O). Improvement in pre–post bronchodilator peripheral airway resistance measured by IOS is associated with complete remission, unlike large airway changes. Longitudinal small airway assessment offers a sensitive tool to predict remission, potentially reflecting residual peripheral inflammation that may prevent it."

Clinical • Asthma • Immunology • Inflammation • Respiratory Diseases

Personalized urticaria care: Endotypes, biomarkers (EADV 2026) - "Twelve years ago, omalizumab was the first advanced treatment option approved for CSU, this fundamentally changed the management of our patients...With the approval of two new treatment options with very different mechanisms of action - the Bruton's tyrosine kinase inhibitor remibrutinib and the IL-4Rα antibody dupilumab – the re-evaluation of a potential personalized urticaria care based on endotypes and biomarkers is necessary...These possible features may include certain disease characteristics, such as the presence of angioedema, co-morbid inducible urticaria or the disease duration, but also biomarkers such as cytokine profiles in the blood and/or skin, specific IgG-/IgE-autoantibody profiles, or other, yet to be identified, markers. These investigations will hopefully lead to the possibility of providing all of our patients with antihistamine-refractory CSU, with a tailored treatment that leads to a rapid disease control."

Biomarker • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review. (PubMed, Front Surg) - "Although dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, depemokimab, and stapokibart have demonstrated substantial clinical efficacy, the optimal duration and maintenance strategy for biologic therapy remain uncertain...However, standardized tapering protocols and high-quality randomized controlled trials are required before routine implementation. Future research should focus on biomarker-guided patient selection, long-term clinical outcomes, and the cost-effectiveness of biologic dose optimization."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Bullous pemphigoid and combined targeted treatments (EADV 2026) - "Illustrative clinical cases are presented across different scenarios. Key Learning Objectives: Understand the dual IgG/IgE immunopathological axis of BP — including the roles of BP180 (NC16A domain) and BP230 as autoantigens, the type 2 inflammatory cascade (IL-4, IL-13, IgE, eosinophils), and how this mechanistic framework directly informs the rationale for biologic intervention with dupilumab and omalizumab Apply a structured, evidence-based treatment algorithm — navigating from EADV S2K first-line corticosteroid strategies through corticosteroid-sparing immunosuppressants, to FDA-approved dupilumab and off-label omalizumab, with guidance on patient selection Evaluate the evidence for combined biologic therapy — critically appraising published combination case series, including identification of optimal candidates for dual biologic blockade Recognize and manage challenging BP subtypes in specialist practice — including drug-induced BP (DPP-4 inhibitors, PD-1/PD-L1..."

Bullous Pemphigoid • Dermatology • Dermatopathology • Geriatric Disorders • Immunology • Inflammation • COL17A1 • IL13 • IL4

Combination biologic therapy in bullous pemphigoid: two case reports and a focused review. (PubMed, Front Immunol) - "In the first case, partial response to omalizumab was followed by complete disease control after the addition of dupilumab, allowing successful corticosteroid discontinuation. In the second case, a patient with concomitant psoriasis achieved marked improvement with dupilumab in combination with ongoing IL-17 inhibition (secukinumab), resulting in effective control of both BP and psoriasis. These observations highlight the benefit of simultaneous targeting of complementary inflammatory pathways, including IgE-mediated, Th2, and Th17 axes. Combination biologic therapy may represent a promising strategy in refractory BP, particularly in patients with complex immunologic profiles or coexisting inflammatory diseases."

Journal • Review • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis • IL17A

Understanding chronic spontaneous urticaria (EADV 2026) - "Until 2025 the unique recommended third line of treatment consists of adding to the antihistamines an incredible drug for CSU, was omalizumab...From such new proposed treatments dupilumab and remibrutinib has been approved recently by the Agencies and offer a great advance...New therapies for CU including both Spontaneous and Inducible Urticarias are welcome Objectives , review the present benefits of registered new treatments for CSU, define the unmet need for new potential useful treatments., define the pathogenic targets to which potential new drugs could be interesting to develop. and Identify the clinical trials in development."

Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • CD200 • IL13 • IL17A • IL4R • IL5 • IL6 • PTGDR2 • SIGLEC8 • TSLP

Association Between Biologic Therapy and Ocular Adverse Events in Chronic Rhinosinusitis with Nasal Polyps (AAO-HNSF 2026) - "Biologics included dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, and depemokimab. Biologic therapy for CRSwNP was associated with increased risk of conjunctivitis, glaucoma, keratitis, and blurred vision, with a borderline increase in ocular irritation, while blepharitis and eyelid rosacea were not significant. These findings support counseling and symptom monitoring, and highlight the need for further mechanistic study and drug-specific risk stratification."

Adverse events • Chronic Rhinosinusitis With Nasal Polyps • Conjunctivitis • Dry Eye Disease • Glaucoma • Immunology • Keratitis • Nasal Polyps • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Respiratory Diseases • Rosacea • Sinusitis